SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Primis Financial Corp. disclosed third quarter 2026 financial results, reporting net income of $8.7 million ($0.35 per diluted share) compared to $6.8 million ($0.28 per diluted share) in Q3 2025, along with comprehensive financial metrics, divisional performance, and year-to-date results.
View raw filing on EDGAR →The Board of Directors declared a quarterly cash dividend of $0.10 per share, payable November 20, 2026 to shareholders of record as of November 6, 2026, marking Primis' sixtieth consecutive quarterly dividend.
View raw filing on EDGAR →Republic Bancorp announced its third quarter and nine-month 2026 financial results on October 23, 2026, via an earnings release (Exhibit 99.1) disclosing net income of $31.1 million and diluted EPS of $1.59 for Q3 2026, representing 4% and 5% increases respectively from Q3 2025. The filing includes detailed segment performance, net interest income analysis, and key financial metrics, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →First Hawaiian, Inc. disclosed its quarterly financial results for the quarter ended September 30, 2026, including net income of $63.7 million ($0.52 per diluted share), balance sheet metrics, and performance ratios. The press release was furnished as Exhibit 99.1 and is the core disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The filing also includes a dividend declaration of $0.26 per share, which is a routine component of quarterly earnings announcements.
View raw filing on EDGAR →The exhibit announces completion of a merger between Perfect Corp. and ProjectNY (Merger Sub), with Perfect as the surviving company. The Merger Agreement was dated July 10, 2026, and became effective on October 23, 2026. Shareholders received US$2.00 per share in cash consideration, and the Company's Class A ordinary shares ceased to be publicly traded. This is a material change of control and acquisition event requiring disclosure under Item 1.01 or 2.01 of the 8-K taxonomy (or equivalent 6-K disclosure).
View raw filing on EDGAR →Winnebago Industries entered into a cooperation agreement with Vision One Fund resolving a shareholder activism dispute, committing to nominate Jay L. Johnson as an independent director, rename and amend the Audit Committee charter, and submit proposals to declassify the Board over three years.
View raw filing on EDGAR →This Item 2.02 disclosure announces NorthEast Community Bancorp's financial results for the three and nine months ended September 30, 2026, with a press release attached as Exhibit 99.1. The filing reports net income of $10.7 million ($0.81 per basic share) for Q3 2026 and $30.4 million ($2.31 per basic share) for the nine-month period, along with detailed balance sheet and operational metrics. This is a standard quarterly earnings release material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The Company entered into a Modification Agreement to materially modify and extend an existing mortgage loan secured by the Hotel Indigo Property, increasing the maximum principal amount by $1,750,000 (from $15,600,000 to $17,350,000), extending the maturity date from June 6, 2027 to June 6, 2028 with two optional 12-month extensions, and modifying interest rate terms.
View raw filing on EDGAR →The Board authorized payment of distributions to holders of Class K, K-I, and K-T common stock, as well as Class K OP Units held by Affiliate Sellers, calculated at a seven percent per annum accrual rate and payable in cash on November 4, 2026, totaling $677,851 for K Shares, $256,731 for K-I Shares, and $22,606 for Class K OP Units.
View raw filing on EDGAR →MetroCity Bankshares issued a press release on October 23, 2026 announcing third quarter 2026 financial results, including net income of $24.3 million ($0.84 per diluted share) and year-to-date net income of $68.7 million ($2.37 per diluted share). The disclosure includes comprehensive quarterly and nine-month results of operations, balance sheet metrics, and key performance indicators, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of a special stockholder meeting held on October 23, 2026, where shareholders voted on three proposals: (1) approval of the Merger Agreement with Smithfield Foods, Inc., which passed with 3,229,773 votes for and 28,025 against; (2) advisory approval of merger-related executive compensation; and (3) adjournment authority. The Merger Proposal was approved by the required vote, making this a material shareholder vote result on a transformative M&A transaction.
View raw filing on EDGAR →This Item 8.01 disclosure concerns supplemental disclosures to a proxy statement regarding a proposed transaction in which New NOVAGOLD would acquire Paulson's 40% interest in Donlin Gold LLC, increasing NOVAGOLD's ownership from 60% to 100%, and current NOVAGOLD shareholders would own approximately 65% of the resulting entity. The filing describes the transaction agreements entered into on July 21, 2026, and the shareholder vote scheduled for November 3, 2026. This constitutes material acquisition activity (increasing ownership to 100% control of Donlin Gold) and a material change of control (restructuring via all-share transaction with New NOVAGOLD as ultimate parent). The supplemental disclosures address shareholder demand letters and provide additional transaction background and governance details, all central to the M&A transaction's disclosure and shareholder approval process.
View raw filing on EDGAR →Elena Verbinskaya, the Company's Chief Accounting Officer and principal accounting officer, is departing effective March 5, 2027, following a mutual agreement on October 20, 2026. The disclosure centers on the departure of a named executive officer responsible for accounting functions, which is material to investors assessing the registrant's financial reporting and internal controls. The explicit statement that the departure is not due to disagreement on accounting matters does not diminish the materiality of losing the principal accounting officer.
View raw filing on EDGAR →Cizzle Brands announces an underwritten public offering of common shares in the United States pursuant to a Form F-10 registration statement filed with the SEC, with concurrent offering in Canada under the LIFE Exemption. The offering involves issuance of new equity securities with pricing and terms to be determined at market. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →The disclosure centers on a one-time cash retention award of $550,000 granted to CFO John Szczepanski pursuant to a letter agreement, with specific vesting conditions and repayment obligations. This is a compensatory arrangement for a named executive officer, fitting the definition of exec_compensation. While Item 5.02 covers multiple event types, the principal disclosed action is the compensation arrangement itself, not a departure or appointment.
View raw filing on EDGAR →Workday completed issuance of $2.5 billion in aggregate principal amount of senior notes across four tranches (2029, 2031, 2033, and 2036 maturities) on October 23, 2026, pursuant to an Underwriting Agreement entered into on October 21, 2026. Net proceeds of approximately $2.47 billion are intended for debt refinancing and general corporate purposes.
View raw filing on EDGAR →Martin J. Bonick's departure as President and CEO effective June 2, 2026, is the principal disclosed action, with the October 19, 2026 Board determination recharacterizing his separation as a termination for "Cause" due to failure to disclose compensation from third parties. While the filing also addresses severance modifications (cancellation of ~$4.5 million in payments and forfeiture of PRSUs), the core event is the executive's departure and the Board's post-hoc determination of cause, making this fundamentally an exec_departure disclosure rather than a compensation arrangement.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly and nine-month financial results for First Capital, Inc. The press release, attached as Exhibit 99.1, announces net income of $5.1 million ($1.53 per diluted share) for Q3 2026 and $14.2 million ($4.25 per diluted share) for the nine-month period, with detailed comparisons to prior-year periods. This is a standard Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →Energy Services of America completed the acquisition of substantially all operating assets of FAMCO, Inc. for a base purchase price of $6.95 million. The filing explicitly states this is a "previously announced acquisition" that was "completed" on October 23, 2026, and the press release confirms the subsidiary FAMCO Acquisition, Inc. has closed the transaction. This is a material acquisition event disclosing completion of a material business combination.
View raw filing on EDGAR →The filing discloses a joinder agreement under which a subsidiary of International Seaways entered into the existing $500 Million RCF as a new guarantor and pledged a VLCC tanker as collateral. While this is technically an amendment to an existing credit facility rather than a new debt issuance, it creates a new direct financial obligation for the subsidiary and materially expands the company's secured debt structure. The substitution of collateral (replacing a previously sold vessel) and the addition of a guarantor represent material changes to the company's financial obligations and credit arrangements.
View raw filing on EDGAR →Manpreet Uppal resigned from the Board of Directors and all Board committees effective October 19, 2026. This is a clear departure of a director from the registrant. While the filing notes the resignation was not due to disagreement, the departure of a board member is material to investors' assessment of governance and leadership continuity.
View raw filing on EDGAR →The filing discloses both a departure (Tim Wilson stepping down as Manager and President effective October 22, 2026) and an appointment (Michael Considine appointed to the same roles effective the same date). While both events occurred, the appointment of a new Manager and President to lead the company is the principal forward-looking action and the more salient disclosure. The appointment of a top executive to lead a company is material to investors assessing management continuity and operational direction.
View raw filing on EDGAR →Sangrix is soliciting shareholder votes for an Extraordinary General Meeting scheduled for November 3, 2026, to approve a 10-for-1 share consolidation with par value adjustment, amendment and restatement of the memorandum and articles of association conditional on the consolidation, and meeting adjournment authority. The share consolidation is being undertaken to address Nasdaq minimum bid price compliance concerns and represents a material capital structure change.
View raw filing on EDGAR →This Item 8.01 disclosure announces the scheduling of shareholder meetings and a Bermuda court sanction hearing for a previously announced business combination in which Transocean will acquire all outstanding common shares of Valaris in exchange for 15.235 shares of Transocean per Valaris share. The filing provides specific dates for the Transocean Meeting and Valaris Court Meeting (November 24, 2026) and the Sanction Hearing (November 26, 2026), with anticipated consummation on or about December 1, 2026. This represents a material acquisition/change of control event that would significantly affect investor assessment of Transocean.
View raw filing on EDGAR →Alpine Income Property Trust disclosed a Preferred Offering of 8.00% Series A Cumulative Redeemable Preferred Stock with net proceeds to be contributed to the Operating Partnership in exchange for Series A Preferred Units, representing a material capital raise with liquidation preference of $25.00 per unit.
View raw filing on EDGAR →Alpine Income Property Trust established two at-the-market (ATM) offering programs: a Preferred Shares ATM program for up to $35 million and a Common Stock ATM program for up to $150 million, representing an aggregate potential dilutive issuance of $185 million in registered equity.
View raw filing on EDGAR →Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments establishing an at-the-market (ATM) offering facility allowing the Company to sell up to $50,000,000 in newly issued common stock over a 36-month period at a 6% discount to VWAP, with multiple purchase mechanisms and an unregistered private placement to accredited investors under Section 4(a)(2) and Rule 506(b) exemptions.
View raw filing on EDGAR →This Item 5.07 filing discloses the complete results of Canopy Growth's 2026 Annual General and Special Meeting of Shareholders held on October 23, 2026, including voting outcomes on seven proposals: election of five directors, appointment of MNP as auditor, share consolidation authorization, advance notice by-law adoption, omnibus incentive plan renewal, advisory vote on NEO compensation, and frequency of future say-on-pay votes. The disclosure is a textbook shareholder vote results filing with detailed vote tallies for each proposal.
View raw filing on EDGAR →MacroGenics disclosed positive interim Phase 1 clinical trial results for MGC026, a B7-H3-directed antibody-drug conjugate, showing a 27% response rate in heavily pretreated SCCHN patients with a manageable safety profile. The company announced plans to initiate a front-line combination study with pembrolizumab in early 2027. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, exec changes, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity, dilutive issuance, litigation, debt/dividend issuance, or workforce reduction. It is clearly operational/strategic in nature—a significant product development update—making operational_other the most appropriate classification.
View raw filing on EDGAR →Jefferson Terminal segment announced a proposed acquisition of DRUbit LLC for approximately $255 million enterprise value, to be financed through a $270 million private debt offering. The transaction includes pro forma financial metrics and 2027 guidance.
View raw filing on EDGAR →NJNG, a wholly-owned subsidiary of New Jersey Resources Corp, issued and sold $50,000,000 of 5.43% Senior Notes due October 22, 2036 in a private placement on October 22, 2026, to refinance short-term debt and fund capital expenditures.
View raw filing on EDGAR →Arcosa completed a merger in which shareholders received $150.00 per share in cash consideration, with aggregate consideration of approximately $7.5 billion. Arcosa became a wholly-owned subsidiary of Parent, constituting a material change of control transaction financed through bridge and term loan facilities totaling $5.75 billion.
View raw filing on EDGAR →Robin Energy announced entry into an agreement to acquire a 2015-built 5,000 cbm LPG Carrier vessel for $18 million from AI OKTO CORP., a Nasdaq-listed entity controlled by the Company's Chairman and CEO. The acquisition represents a material capital deployment and fleet expansion for the ship-owning company, with expected delivery in Q4 2026 and funding from cash on hand. This is a discrete M&A transaction requiring board approval and special committee review due to the related-party nature of the deal.
View raw filing on EDGAR →The Board approved and filed a one-for-nine reverse stock split of the company's common stock, which was previously authorized by stockholders on July 24, 2026. The reverse stock split involves an amendment to the Certificate of Incorporation and materially affects the company's capital structure, share count, and trading mechanics.
View raw filing on EDGAR →AI OKTO announced the sale of the Dream Arrax, a 5,000 cbm LPG Carrier vessel, for $18 million to a subsidiary of Robin Energy Ltd. This is a material disposition of a significant asset. The announcement notes that following this transaction, the Company's fleet will consist of only one vessel, representing a substantial reduction in the registrant's operating assets and business scope. The transaction was approved by both boards and special committees of independent directors, and delivery is expected in Q4 2026.
View raw filing on EDGAR →The exhibit is a press release announcing a special dividend of $3.50 per common share declared by AI OKTO Corp.'s board of directors, payable to shareholders of record on November 2, 2026, with payment expected November 25, 2026. The dividend represents more than 25% of the current trading price and is material to investors as it constitutes a significant return of capital and affects share valuation and trading mechanics (due bills).
View raw filing on EDGAR →Ionis disclosed positive Phase 3 clinical trial data for sefaxersen, a partnered investigational drug licensed to Roche, showing a statistically significant 43.1% reduction in proteinuria in IgA nephropathy patients with a consistent safety profile. This material clinical milestone affects investor assessment of the drug's commercial potential and Ionis' future royalty and milestone payments from the partnership.
View raw filing on EDGAR →BlackRock Private Credit Fund disclosed an unregistered private placement of 250,520.94 Institutional Class Shares for $5,894,457 to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions. This capital raise represents dilution to existing shareholders.
View raw filing on EDGAR →BlackRock Private Credit Fund declared a regular distribution on October 22, 2026, specifying per-share amounts for Institutional, Class S, and Class D shares, with a record date of October 29, 2026 and payment date of November 25, 2026. Shareholders may elect cash payment or reinvestment through the Fund's distribution reinvestment plan.
View raw filing on EDGAR →This Item 8.01 disclosure announces the scheduling of shareholder meetings and a Bermuda court sanction hearing for a previously announced business combination between Valaris and Transocean. The filing details the acquisition structure (Transocean acquiring all Valaris shares at 15.235 shares per Valaris share via a scheme of arrangement), the scheduled voting dates (November 24, 2026), and the anticipated closing date (December 1, 2026). This constitutes material M&A activity—specifically the advancement toward completion of a material acquisition that would result in a change of control of Valaris.
View raw filing on EDGAR →This press release announces positive three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate, showing 89% vaccine target precision, sustained T-cell responses, and durable clinical responses in advanced melanoma patients. While the disclosure reports clinical trial results rather than financial results or a discrete corporate event, it represents a material operational milestone for a clinical-stage biotech company—the data supports advancement of the company's lead asset and validates its AI-Immunology platform technology. This is neither a periodic financial report nor a traditional earnings release, but rather a material clinical/operational development that would affect investor assessment of the company's pipeline and technology platform.
View raw filing on EDGAR →The Board approved significant increases in annual base salaries for three named executives (CEO Dr. Nijhawan from $357,696 to $657,423, President Dr. Brooks from $335,340 to $591,681, and CFO Weiler from $300,000 to $525,938), retroactive to July 1, 2026. These represent material compensatory arrangements disclosed under Item 5.02(e), with increases of approximately 84%, 76%, and 75% respectively—the first adjustments since 2023. The disclosure also notes that 90% of the CEO's salary continues to be issued as fully vested restricted share units.
View raw filing on EDGAR →Wynn Resorts' indirect subsidiary Wynn Macau (Macau) S.A. entered into a subscription agreement to commit capital investment of up to MOP 1,365,030,000 to a Macau government-sponsored limited partnership fund. The investment constitutes non-gaming capital commitment under the company's gaming concession contract with the Macau government dated December 16, 2022. This is a material operational and strategic commitment to fulfill regulatory obligations in a key jurisdiction, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types—it is a material capital commitment and regulatory compliance matter best classified as operational_other.
View raw filing on EDGAR →ENB Financial Corp disclosed third-quarter 2026 earnings via a press release attached as Exhibit 99, reporting net income of $6.913 million (up 16.8% YoY) and diluted EPS of $1.21 (up from $1.04). The filing explicitly states this is an earnings release for Q3 2026 issued on October 22, 2026, and is disclosed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The press release includes comprehensive financial results, balance sheet data, and performance metrics.
View raw filing on EDGAR →This press release announces preclinical data presented at ESMO 2026 demonstrating synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, with plans to add an ovarian cancer arm to the ongoing Phase 1/2a clinical trial. The disclosure is a material operational/strategic milestone—positive preclinical results supporting expansion of a lead program into a new indication—but does not fit the discrete event categories (no M&A, no exec change, no financial obligation, no litigation). The data presentation and planned trial expansion represent a significant development in the company's therapeutic pipeline and clinical strategy.
View raw filing on EDGAR →This shareholder letter discloses multiple material developments: (1) preliminary unaudited financial position as of September 30, 2026 ($11.0M cash, $2.5M liabilities, $3.7M operating loss for nine months); (2) $10.5M raised through equity line facility; (3) LayerBio's planned Phase 2 trial enrollment of OcuRing™-K before year-end; and (4) GridFeed's establishment as a standalone subsidiary with entry into AI data center power optimization. While the financial metrics are preliminary and unaudited, the combination of capital raise, clinical trial advancement, and strategic restructuring (GridFeed subsidiary formation) constitutes material disclosure affecting investor assessment. However, the event does not fit neatly into a single taxonomy category—it is neither a discrete earnings release (preliminary, unaudited, not a complete financial statement), nor a periodic report (it is a shareholder letter), nor a single operational or financial event. The domain is mixed (financial position, clinical progress, strategic restructuring), making `other_material` the most appropriate classification.
View raw filing on EDGAR →UY Scuti Acquisition Corp. entered into a material definitive agreement on October 22, 2026, in connection with its pending business combination. The agreement involves financing through the issuance of unsecured promissory notes, including the Isdera HK Note for $900,000 and the Xinghui Note for up to $200,000.
View raw filing on EDGAR →T3 Defense received a Nasdaq notice on August 20, 2026 that it failed to maintain the minimum $10 million stockholders' equity requirement under Nasdaq Listing Rule 5450(b)(1)(A), creating delisting risk. Although the company claims to have regained compliance as of September 30, 2026 through warrant exercises that eliminated the liability-classified warrant position, the disclosure explicitly states "if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting" and "There can be no assurance that Nasdaq will determine that the Company has regained compliance." This is a material delisting-risk disclosure, not a resolved delisting matter.
View raw filing on EDGAR →The exhibit discloses an unregistered private placement of 2,751,789 Class A ordinary shares at $1.8170 per share for $5,000,000 in aggregate gross proceeds, relying on Section 4(a)(2) of the Securities Act and Regulation D Rule 506(b). This is a classic dilutive equity issuance. The transaction also involves a related-party component (Yang Investor controlled by CEO Dr. Tingjun Yang subscribing for 1,157,823 shares), which was reviewed and approved by the Audit Committee and Board, but the primary event is the unregistered equity sale itself.
View raw filing on EDGAR →The exhibit announces a 2-for-1 share consolidation approved by the board on October 10, 2026, effective October 30, 2026. This is a governance and capital structure event involving a change to the company's authorized and issued share capital, par value, and CUSIP number. While not a traditional executive appointment, departure, or compensation matter, it is a material governance action affecting all shareholders' holdings and the company's capitalization structure.
View raw filing on EDGAR →